These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31157557)

  • 1. Osteoprotegerin and osteopontin levels, but not gene polymorphisms, predict mortality in cardiovascular diseases.
    Lin JF; Wu S; Juang JJ; Chiang FT; Hsu LA; Teng MS; Cheng ST; Huang HL; Ko YL
    Biomark Med; 2019 Jun; 13(9):751-760. PubMed ID: 31157557
    [No Abstract]   [Full Text] [Related]  

  • 2. IL1RL1 single nucleotide polymorphism predicts sST2 level and mortality in coronary and peripheral artery disease.
    Lin JF; Wu S; Juang JJ; Chiang FT; Hsu LA; Teng MS; Cheng ST; Huang HL; Sun YC; Liu PY; Ko YL
    Atherosclerosis; 2017 Feb; 257():71-77. PubMed ID: 28110258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.
    Tousoulis D; Siasos G; Maniatis K; Oikonomou E; Kioufis S; Zaromitidou M; Paraskevopoulos T; Michalea S; Kollia C; Miliou A; Kokkou E; Papavassiliou AG; Stefanadis C
    Int J Cardiol; 2013 Sep; 167(5):1924-8. PubMed ID: 22640692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of serum FGF-23, klotho, fetuin-A, osteopontin, osteoprotegerin and hs-CRP levels with coronary artery disease.
    Göçer K; Aykan AÇ; Kılınç M; Göçer NS
    Scand J Clin Lab Invest; 2020 Jul; 80(4):277-281. PubMed ID: 32077762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of osteopontin and osteoprotegerin levels in abdominal aortic aneurysm patients].
    Czyzewska-Buczyńska A; Zuk N; Bałasz S; Witkiewicz W
    Przegl Lek; 2013; 70(3):102-5. PubMed ID: 24003660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy.
    Kadoglou NP; Kottas G; Lampropoulos S; Vitta I; Liapis CD
    Clin Drug Investig; 2014 Mar; 34(3):165-71. PubMed ID: 24307429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of osteopontin, and osteoprotegerin mRNA in epicardial adipose tissue between patients with severe coronary artery disease and aortic valvular stenosis: association with HDL subclasses.
    Luna-Luna M; Cruz-Robles D; Ávila-Vanzzini N; Herrera-Alarcón V; Martínez-Reding J; Criales-Vera S; Sandoval-Zárate J; Vargas-Barrón J; Martínez-Sánchez C; Tovar-Palacio AR; Fragoso JM; Carreón-Torres E; Vargas-Alarcón G; Pérez-Méndez Ó
    Lipids Health Dis; 2017 Aug; 16(1):156. PubMed ID: 28821297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular calcification biomarkers and peripheral arterial disease.
    Kapetanios D; Karkos C; Giagtzidis I; Papazoglou K; Kiroplastis K; Spyridis C
    Int Angiol; 2016 Oct; 35(5):455-9. PubMed ID: 26044839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus.
    Barchetta I; Ceccarelli V; Cimini FA; Bertoccini L; Fraioli A; Alessandri C; Lenzi A; Baroni MG; Cavallo MG
    J Endocrinol Invest; 2019 May; 42(5):513-520. PubMed ID: 30132286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism rs2073618 of the osteoprotegerin gene as a potential marker of subclinical carotid atherosclerosis in Caucasians with type 2 diabetes mellitus.
    Pleskovič A; Ramuš SM; Pražnikar ZJ; Šantl Letonja M; Cokan Vujkovac A; Gazdikova K; Caprnda M; Gaspar L; Kruzliak P; Petrovič D
    Vasa; 2017 Aug; 46(5):355-362. PubMed ID: 28593808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
    Bozic M; Méndez-Barbero N; Gutiérrez-Muñoz C; Betriu A; Egido J; Fernández E; Martín-Ventura JL; Valdivielso JM; Blanco-Colio LM;
    Atherosclerosis; 2018 Mar; 270():13-20. PubMed ID: 29407881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals.
    Stępień E; Wypasek E; Stopyra K; Konieczyńska M; Przybyło M; Pasowicz M
    Clin Biochem; 2011 Jul; 44(10-11):826-31. PubMed ID: 21539822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated osteopontin levels in patients with peripheral arterial disease.
    Koshikawa M; Aizawa K; Kasai H; Izawa A; Tomita T; Kumazaki S; Tsutsui H; Koyama J; Shimodaira S; Takahashi M; Ikeda U
    Angiology; 2009; 60(1):42-5. PubMed ID: 18388057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Emerging Role of Bone Markers in Diagnosis and Risk Stratification of Patients With Coronary Artery Disease.
    Kosmopoulos M; Paschou SA; Grapsa J; Anagnostis P; Vryonidou A; Goulis DG; Siasos G
    Angiology; 2019 Sep; 70(8):690-700. PubMed ID: 30696256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease.
    Kadoglou NPE; Kapetanios D; Korakas E; Valsami G; Tentolouris N; Papanas N; Lambadiari V; Karkos C
    Cardiovasc Diabetol; 2022 Sep; 21(1):171. PubMed ID: 36050687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin SNP associations with coronary artery disease and ischemic stroke risk: a meta-analysis.
    Wu J; Li X; Gao F; Gao S; Lyu J; Qiang H
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32955093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin and osteoprotegerin levels in type 2 diabetes and their association with cardiovascular autonomic function.
    Maser RE; Lenhard MJ; Pohlig RT; Balagopal PB
    J Diabetes Complications; 2016 Apr; 30(3):507-10. PubMed ID: 26775555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin and Osteopontin Serum Levels are Associated with Vascular Function and Inflammation in Coronary Artery Disease Patients.
    Maniatis K; Siasos G; Oikonomou E; Vavuranakis M; Zaromytidou M; Mourouzis K; Paraskevopoulos T; Charalambous G; Papavassiliou AG; Tousoulis D
    Curr Vasc Pharmacol; 2020; 18(5):523-530. PubMed ID: 31642412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention.
    Siller-Matula J; Lang IM; Schoergenhofer C; Roest M; Jilma B
    Thromb Haemost; 2017 Aug; 117(9):1730-1738. PubMed ID: 28726980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin as a marker of atherosclerosis: a systematic update.
    Hosbond SE; Poulsen TS; Diederichsen AC; Nybo M; Rasmussen LM; Mickley H
    Scand Cardiovasc J; 2012 Aug; 46(4):203-11. PubMed ID: 22506827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.